# AlmegaPL (Nannochloropsis oculata Algae)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/almegapl
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-29
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** Nannochloropsis oculata algae oil, Nannochloropsis oculata extract, Microalgae EPA, Polar lipid EPA, Algal omega-3, Marine microalgae oil, Nannochloropsis EPA oil, Polar lipid omega-3

## Overview

AlmegaPL is a marine algae oil extract from Nannochloropsis oculata containing EPA and DHA omega-3 fatty acids. It increases omega-3 index levels and supports [cardiovascular health](/ingredients/condition/heart-health) through enhanced membrane phospholipid incorporation.

## Health Benefits

• Increased Omega-3 Index by 16% (from 4.96% to 5.75%) in 12 weeks based on RCT evidence (n=104)
• Reduced total cholesterol by 3% and V[LDL cholesterol](/ingredients/condition/heart-health) by 25% in healthy adults (moderate evidence from RCT)
• Decreased triglycerides by 14.9% in normolipidemic adults (preliminary evidence from cohort study)
• Reduced hip circumference and body weight in 12-week RCT (moderate evidence)
• Improved vigor scores without raising LDL cholesterol, unlike DHA-containing sources (moderate evidence)

## Mechanism of Action

AlmegaPL provides EPA and DHA fatty acids that incorporate into cell membrane phospholipids, particularly in red blood cells and cardiac tissue. These omega-3s modulate [inflammatory pathway](/ingredients/condition/inflammation)s by competing with arachidonic acid for cyclooxygenase and lipoxygenase enzymes, reducing pro-inflammatory eicosanoid production. The algae-derived omega-3s also activate PPAR-alpha receptors, enhancing fatty acid oxidation and improving lipid [metabolism](/ingredients/condition/weight-management).

## Clinical Summary

A randomized controlled trial (n=104) demonstrated that AlmegaPL supplementation increased omega-3 index from 4.96% to 5.75% over 12 weeks, representing a 16% improvement. The same study showed moderate evidence for 3% reduction in total cholesterol and 25% reduction in V[LDL cholesterol](/ingredients/condition/heart-health) in healthy adults. Preliminary cohort data suggests 14.9% triglyceride reduction in normolipidemic individuals. The evidence base is emerging but limited to single-study outcomes for most benefits.

## Nutritional Profile

AlmegaPL (Nannochloropsis oculata microalgae extract) is characterized by a phospholipid-bound omega-3 fatty acid matrix, which distinguishes it from standard fish oil or algal oil triglyceride forms. Key bioactive components include: EPA (eicosapentaenoic acid) as the dominant omega-3, delivered primarily in phospholipid form (phosphatidylcholine and phosphatidylethanolamine bound), which enhances intestinal absorption and lymphatic transport compared to triglyceride-bound EPA — bioavailability studies suggest phospholipid-bound EPA achieves superior incorporation into red blood cell membranes and plasma at lower doses. DHA is present in minor amounts, as Nannochloropsis species are EPA-dominant. The extract also contains glycolipids and betaine lipids native to the microalgae cell membrane. Carotenoid content includes violaxanthin and zeaxanthin, both naturally occurring in Nannochloropsis oculata, with [antioxidant](/ingredients/condition/antioxidant) and potential [anti-inflammatory](/ingredients/condition/inflammation) roles. Chlorophyll derivatives are present in small quantities. Protein content in the whole algae biomass is approximately 25–35% by dry weight, though the AlmegaPL extract is lipid-fraction concentrated, reducing protein contribution in the final ingredient. Mineral content from the source algae includes iodine, calcium, magnesium, and iron, though concentrations in the extracted lipid fraction are minimal. The phospholipid delivery matrix is the primary distinguishing nutritional feature, enabling lower effective doses (typically 1–1.5g/day in clinical studies) to produce measurable omega-3 index increases compared to standard fish oil formulations.

## Dosage & Preparation

Clinically studied doses include 1000-1100 mg/day in capsule form. The 12-week RCT used AlmegaPL standardized to >15% polar lipids and >25% EPA w/w. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

AlmegaPL appears well-tolerated in clinical studies with no serious adverse events reported in the 12-week RCT. As an algae-derived omega-3 source, it may interact with anticoagulant medications like warfarin by enhancing bleeding risk, though this interaction is theoretical. Mild gastrointestinal effects such as nausea or fishy aftertaste may occur, similar to other omega-3 supplements. Pregnancy and lactation safety has not been established in clinical trials.

## Scientific Research

A 12-week double-blind RCT (n=120 randomized, 104 completers) demonstrated significant increases in Omega-3 Index and EPA levels, with reductions in total cholesterol, VLDL, and body measurements (PMC7353404). A post-market cohort study confirmed cholesterol reduction and 14.9% triglyceride decrease at 1000-1100 mg/day doses (PMID: 38379539; NCT05267301).

## Historical & Cultural Context

No historical or traditional medicine use was identified for AlmegaPL or Nannochloropsis oculata in the research. This is a modern branded extract developed specifically as a dietary supplement.

## Synergistic Combinations

CoQ10, astaxanthin, vitamin E, magnesium, plant sterols

## Frequently Asked Questions

### How much does AlmegaPL increase omega-3 levels?

Clinical studies show AlmegaPL increases omega-3 index by 16% over 12 weeks, raising levels from 4.96% to 5.75%. This improvement places users closer to the optimal omega-3 index range of 8-12% for cardiovascular protection.

### What's the difference between AlmegaPL and fish oil?

AlmegaPL is derived from Nannochloropsis oculata algae rather than fish, making it suitable for vegetarians and vegans. It provides the same EPA and DHA fatty acids as fish oil but without potential heavy metal contamination or fishy aftertaste commonly associated with marine-derived supplements.

### How long does AlmegaPL take to work?

Omega-3 index improvements with AlmegaPL become measurable within 4-6 weeks of supplementation. The full 16% increase in omega-3 levels was achieved after 12 weeks of consistent daily supplementation in clinical trials.

### Can AlmegaPL lower cholesterol levels?

Clinical evidence shows AlmegaPL reduces total cholesterol by 3% and VLDL cholesterol by 25% in healthy adults. Additionally, preliminary studies suggest a 14.9% reduction in triglycerides, though more research is needed to confirm these lipid-lowering effects.

### What is the recommended dosage of AlmegaPL?

The clinical study achieving 16% omega-3 index improvement used a specific daily dosage over 12 weeks, though exact dosing protocols vary by manufacturer. Typical algae oil supplements provide 250-500mg combined EPA/DHA per serving, but follow product-specific recommendations for optimal results.

### Is AlmegaPL safe to take with blood pressure or cholesterol medications?

AlmegaPL derived from Nannochloropsis oculata algae is generally well-tolerated, but since it can lower VLDL cholesterol and triglycerides, individuals taking statin or fibrate medications should consult their healthcare provider to monitor combined effects. There are no well-documented contraindications with common cardiovascular medications, though coordinated medical oversight is recommended given its lipid-modifying properties.

### Who would benefit most from AlmegaPL supplementation?

AlmegaPL is most beneficial for adults with suboptimal omega-3 levels (Omega-3 Index below 6%), elevated triglycerides or VLDL cholesterol, or those seeking cardiovascular and metabolic support without consuming fish. It may also appeal to vegans, vegetarians, and individuals with fish allergies who want a plant-based omega-3 source with clinical evidence.

### What does the clinical research show about AlmegaPL's effectiveness?

Clinical evidence from a randomized controlled trial (n=104) demonstrates that AlmegaPL increased the Omega-3 Index by 16% over 12 weeks and reduced total cholesterol by 3% and VLDL cholesterol by 25% in healthy adults. Additional research shows a 14.9% reduction in triglycerides in normolipidemic individuals, though triglyceride evidence comes from preliminary cohort studies rather than controlled trials.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*